FDA Advisers Consider Novavax COVID-19 Vaccine This Week FDA Advisers Consider Novavax COVID-19 Vaccine This Week

An FDA panel will consider Novavax ' s COVID two-dose, protein-based vaccine this week, looking at some reports of adverse reactions, including rare events of myocarditis and pericarditis.WebMD Health News
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news